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Spinocerebellar ataxia type 17 (SCA17) is a rare autosomal dominant neurodegenerative
disease caused by a CAG repeat expansion in the TATA-box binding protein gene
(TBP). The disease has a varied age at onset and clinical presentation. It is distinct
from other SCAs for its association with dementia, psychiatric symptoms, and some
patients presenting with chorea. For this reason, it is also called Huntington’s disease-
like 4 (HDL-4). Here we examine the distribution of SCA17 allele repeat sizes in a
United Kingdom-based cohort with ataxia and find that fully penetrant pathogenic
alleles are very rare (5 in 1,316 chromosomes; 0.38%). Phenotype-genotype correlation
was performed on 30 individuals and the repeat structure of their TBP genes was
examined. We found a negative linear correlation between total CAG repeat length
and age at disease onset and, unlike SCA1, there was no correlation between the
longest contiguous CAG tract and age at disease onset. We were unable to identify
any particular phenotypic trait that segregated with particular CAG/CAA repeat tract
structures or repeat lengths. One individual within the cohort was homozygous for
variable penetrance range SCA17 alleles. This patient had a similar age at onset to
heterozygotes with the same repeat sizes, but also presented with a rapidly progressive
dementia. A pair of monozygotic twins within the cohort presented 3 years apart with
the sibling with the earlier onset having a more severe phenotype with dementia and
chorea in addition to the ataxia observed in their twin. This appears to be a case of
variable expressivity, possibly influenced by other environmental or epigenetic factors.
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Finally, there was an asymptomatic father with a severely affected child with an age at
onset in their twenties. Despite this, they share the same expanded allele repeat sizes
and sequences, which would suggest that there is marked difference in the penetrance
of this 51-repeat allele. We therefore propose that the variable penetrance range extend
from 48 repeats to incorporate this allele. This study shows that there is variability in the
presentation and penetrance of the SCA17 phenotype and highlights the complexity of
this disorder.
Keywords: PolyQ, ataxia, CAG repeat expansions, SCA17, neurodegeneration, genetic counseling
INTRODUCTION
Spinocerebellar ataxia type 17 (SCA17; OMIM #607136) is a
rare autosomal dominant neurodegenerative disorder caused
by a CAG repeat expansion in exon 3 of the TBP that
ultimately results in a loss of coordination and balance.
The disease presents with various clinical symptoms at a
broad range of ages at onset (3–75 years) (Stevanin and
Brice, 2008). SCA17 is characterized by ataxia, pyramidal and
extrapyramidal signs, cognitive impairments, psychosis, and
seizures as well as involuntary movements including chorea
and dystonia. It is distinct from other SCAs for its association
with dementia, psychiatric symptoms, and in some patients
choreic movements, hence it is also named HDL-4 (Stevanin
and Brice, 2008). Brain MRI shows variable atrophy of the
cerebral cortex, brain stem, and cerebellum (Rolfs et al., 2003;
Toyoshima et al., 2004; Brockmann et al., 2012; Origone et al.,
2018).
Typically, normal alleles have 25–40 repeats, whilst pathogenic
SCA17 alleles have 49 repeats or more (Toyoshima et al.,
1993). The intervening alleles (41–48 repeats) may constitute
an intermediate range with variable penetrance (Toyoshima and
Takahashi, 2018). Symptomatic individuals have been reported
with 41 and 42 CAG/CAA repeats (Nanda et al., 2007; Nolte
et al., 2010; Doherty et al., 2014, 2016; Origone et al., 2018),
whilst asymptomatic individuals have been reported with 43–
49 CAG/CAA repeats (Nakamura et al., 2001; Zühlke C. et al.,
2003; Oda et al., 2004; Zühlke et al., 2005; Mariotti et al.,
2007). The largest reported CAG/CAA repeat size to date is
66 CAG/CAA repeats (Maltecca et al., 2003). The gap between
normal and expanded repeat alleles is very narrow and, combined
with variable penetrance, makes it difficult to define an absolute
cut-off for the pathogenic CAG/CAA repeat number in SCA17.
Indeed, diagnosing SCA17 patients is often hampered by non-
penetrance especially when the CAG/CAA repeat number is
low. Variable penetrance is also observed in Huntington’s disease
where pathogenic alleles have reduced penetrance between 36
and 39 repeats (Langbehn et al., 2004), whilst full penetrance
alleles have ≥40 repeats.
The structure of the repeat tract in the TBP gene is relatively
complex and can be segmented into five domains (I–V),
Abbreviations: CAA, cytosine, adenine, adenine; CAG, cytosine, adenine,
guanine; HDL-4, Huntington’s disease-like 4; MRI, magnetic resonance imaging;
PCR, polymerase chain reaction; PolyQ, polyglutamine; SCA, spinocerebellar
ataxia; STR, short tandem repeat; TBP, TATA-box binding protein.
consisting of combinations of CAG and CAA codons, which
both encode glutamine leading to a pure PolyQ tract (Figure 1;
Gostout et al., 1993; Gao et al., 2008). The (CAA/CAG/CAA)
Domain III interruption between the polymorphic CAG repeats
in Domains II and IV is present in all expanded alleles that are
stably transmitted (Toyoshima et al., 1993) and its loss may lead
to repeat instability (Zühlke et al., 2001, 2005; Maltecca et al.,
2003). Anticipation is less common in SCA17, most likely due
to the complex structure of the repeat tract and presence of CAA
interruptions (Toyoshima et al., 1993; Fujigasaki et al., 2001; Rolfs
et al., 2003).
Patients with 43–47 CAG/CAA repeats tend to have a
parkinsonian phenotype (Kim et al., 2009; Chen et al., 2010),
whilst those with 43–50 CAG/CAA repeats tend to have a
phenotype resembling Huntington’s disease with psychiatric
problems or dementia, parkinsonism and chorea (Stevanin et al.,
2003; Bauer et al., 2004; Toyoshima et al., 2004). To date,
however, there has been no association between particular repeat
configurations and certain SCA17 phenotypic traits.
In this study, we examine the distribution of SCA17 allele
sizes in a large United Kingdom-based cohort with ataxia
and found that 38 individuals (5.78%) have pathogenic alleles
in the variable or fully penetrant range (≥41 repeats), with
only five patients (0.76%) in the fully penetrant (≥49 repeats)
range. We selected a sub-cohort of 30 individuals with SCA17
alleles ≥41 repeats for cloning and sequencing to determine
the repeat structure of their alleles. A diverse distribution of
repeat configurations was observed across all cloned individuals
and the CAA interruptions were present in all clones. Within
our cohort we could not identify any phenotypic trait that
segregated with particular CAG/CAA repeat tract structures or
repeat lengths. We found that there was a negative correlation
between total CAG/CAA repeat length and age at onset.
Within our cohort there were three interesting sets of cases.
The first was a patient who was homozygous for SCA17
alleles in the variable penetrance range. They had an age
at onset similar to heterozygotes with the same repeat sizes,
but also presented with a rapidly progressive dementia. In a
second family there were a pair of monozygotic twins. They
presented 3 years apart, with the sibling with an earlier onset
having a more severe phenotype with dementia and chorea
in addition to ataxia. Finally, there was an asymptomatic
father with a severely affected child with an age at onset in
their twenties. Despite this, they share the same expanded
allele repeat sizes and sequences, which would suggest that
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FIGURE 1 | CAG/CAA repeat configuration in the TBP gene. SCA17 is caused by CAG repeat expansion in the TATA-box binding protein gene (TBP). The repeat
tract is characterized by CAA interruptions and has a typical configuration as shown, and can be segmented into Domain I (red), Domain II (brown), Domain III
(green), Domain IV (blue), and Domain V (purple) (Gostout et al., 1993; Gao et al., 2008). Domains II and IV are polymorphic CAG repeats.
there is marked difference in the penetrance of this 51-
repeat allele. We would therefore propose that the variable
penetrance range extend from 48 repeats to incorporate this
allele.
RESULTS
SCA17 Allele Distribution Within a
United Kingdom Cohort
The Neurogenetics Unit at The National Hospital for Neurology
and Neurosurgery, London performed SCA17 diagnostic tests
on 658 DNA samples, comprising 1,316 discrete chromosomes.
The SCA17 alleles within the cohort were distributed as shown
in Figure 2, with the most frequent allele having 38 repeats
(n = 354) and 34 alleles from 33 individuals falling within the
variable penetrance range between 41 and 48 repeats. An enlarged
view of alleles in the variable and full penetrance range (41–
57 repeats, n = 39) is shown in the Figure 2 insert. The most
frequent variable penetrance allele had 41 repeats (n = 14). Only
five alleles from five patients were within the fully penetrant
pathogenic range – two with 49 repeats and one each with 50, 54,
and 57 repeats. The average SCA17 allele size was 37 ± 2 repeats
(mean ± standard deviation) and alleles ranged from 24 to 57
repeats.
SCA17 Clone Sequence Analysis
In order to sequence the repeat regions from SCA17 alleles, a
cloning strategy similar to that previously described for SCA1
was devised (Menon et al., 2013). 467 clones with 61 unique
repeat region sequences were analyzed from 30 individuals
with variable or fully penetrant SCA17 alleles (Supplementary
Table S1). Since the number of clones sequenced for each
individual differed, clone numbers were expressed as a percentage
to account for clone depth (Supplementary Table S2). The most
frequent allele, representing 10% of all clones, had 38 CAG/CAA
repeats, whilst the most frequent variable penetrance allele
represented 6.2% of all clones and had 45 CAG/CAA repeats.
Two alleles of 51 and 57 CAG/CAA repeats were both the most
frequent fully penetrant alleles representing 1.9% of all clones.
A diverse distribution of repeat configurations was observed
for all individuals and all repeat configurations contained CAA
interruptions. Although it has been proposed that loss of
the (CAA/CAG/CAA) Domain III interruption may lead to
instability (Zühlke et al., 2001; Maltecca et al., 2003), the domain
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FIGURE 2 | Frequency distribution of SCA17 allele sizes from diagnostic
fragment analysis performed on a United Kingdom cohort at the
Neurogenetics Unit, National Hospital for Neurology and Neurosurgery,
London. SCA17 alleles from 1,316 discrete chromosomes were analyzed by
fragment analysis. The main graph shows the frequency of all alleles tested
whilst the inset depicts an enlarged view of the alleles in the variable and fully
penetrant range (41–57 repeats, n = 39). Normal alleles (24–40 repeats,
n = 1277) are plotted in blue, whilst variable and fully penetrant alleles are
plotted in brown. The SCA17 alleles ranged from 24 to 57 repeats, with a
mean allele size of 37 ± 2 repeats (mean ± standard deviation). The most
frequent allele had 38 repeats (n = 354), whilst the most frequent variable
penetrance allele had 41 repeats (n = 14). Only five alleles were within the fully
penetrant pathogenic range (≥49 repeats).
configuration 1–2–5 was only observed in 6 out of 46 (13%) of
fully penetrant alleles and not at all in variable penetrant alleles.
Within each individual there were different repeat configurations
observed for each allele, however, the corresponding CAG/CAA
repeat sizes varied by a maximum of four repeats, confirming
the stability and low somatic mosaicism observed by fragment
analysis (data not shown). We had SCA17 allele sequences of four
patients from a cohort in Rome, Italy (Supplementary Table S3).
Interestingly, two of these patients, G31 and G32, lacked the final
(CAA)(CAG) Domain V interruption seen in all clones from our
cohort bar one.
Age at Disease Onset Is Negatively
Correlated With Total SCA17 CAG/CAA
Repeat Length
For the 30 individuals that were cloned, age at disease
onset information was available for 21 patients where there
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FIGURE 3 | Correlation between SCA17 pathogenic allele size and age at disease onset. Age at disease onset data was available for 21 SCA17 patients that had
been both analyzed by fragment sizing and clone sequencing. Pathogenic allele size as determined by fragment sizing shows a negative correlation with respect to
age at onset and a good fit to the linear model (R2 = 0.595) (A). Cloning and sequencing the SCA17 alleles permits the calculation of the mean pathogenic allele
size, rounded to the nearest whole repeat, based on the total length of the CAG/CAA repeat tract sequence. Mean pathogenic allele size as determined by clone
sequencing also shows a negative correlation with respect to age at onset and an improved fit to the linear model (R2 = 0.6005) (B). Comparing the SCA17
pathogenic allele sizes determined by these two methods there is a very significant correlation between the two and a high-quality fit to the linear model
(R2 = 0.9935) (C). The bold line depicts the linear model fit result and the 95% confidence interval bounds are shown by the narrow line and shaded in gray.
were no other confounding factors or differential diagnoses
(Supplementary Table S4). For instance, individual #8 had an
age at onset of 20 years which did not correspond with their
SCA17 allele size of 41 repeats. Subsequent tests revealed they had
a homozygous nonsense mutation (c.13642C > T; p.Gln4548∗;
NM_182961.2) in exon 78 of the SYNE1 gene suggesting a
genetic diagnosis of ARCA1/SCAR8. We examined the influence
of the repeat length on the patients’ age at onset, finding a
negative correlation between the age at disease onset and the
SCA17 pathogenic allele size as determined by fragment sizing
(Figure 3A), with a Pearson correlation coefficient r = −0.7713
(significant at the 0.0001 level) and a good fit to the linear
model (A = −2.6, b = 162.9, R2 = 0.595). Clone sequencing
allows us to determine the mean pathogenic allele size, rounded
to the nearest whole repeat, based on the total length of the
CAG/CAA repeat tract sequence. This approach also displays
a negative correlation between the age at onset and the mean
pathogenic allele size (Figure 3B), with a Pearson correlation
coefficient r = −0.7749 (significant at the 0.0001 level) and
an improved fit to the linear model (A = −2.554, b = 160.7,
R2 = 0.6005). Comparing the SCA17 allele sizing by fragment
analysis and clone sequencing we observe, as expected, a very
significant correlation between the two methods, with a Pearson
correlation coefficient r = 0.9968 (significant at the 0.0001 level)
and a high-quality fit to the linear model (A = 0.9652, b = 1.59,
R2 = 0.9935) (Figure 3C). To examine whether the longest
contiguous CAG repeat stretch was the main determinant of
the age at onset, in the same way that we have previously
observed for SCA1 (Menon et al., 2013), the longest CAG repeat
stretch determined by clone sequencing was plotted against age
at onset (Supplementary Figure S1). There was no correlation
between these two variables – Pearson correlation coefficient
r =−0.004811.
Phenotype Distribution of Cloned SCA17
Patients
Clinical information was available for 25 of the individuals
from whom we cloned SCA17 alleles. One individual, Subject
#5, was asymptomatic at the age of 50 years. Phenotypes were
defined based on the presence of ataxia, dementia, chorea,
and/or parkinsonism. The distribution of these phenotypes
across the cohort is shown as a Venn diagram in Figure 4. As
expected, the majority of subjects were ataxic (21 out of 25,
84%). Two subjects, #7 and #12, had parkinsonism only (8%
of the cohort). There was no apparent segregation of particular
phenotypic traits with CAG/CAA repeat tract structures or repeat
lengths.
Patient Homozygous for Variable
Penetrance SCA17 Alleles
Patient #23 has SCA17 alleles of 41 and 42 CAG/CAA
repeats, which both lie within the variable penetrance
range. Indeed, 41 CAG/CAA repeats is the largest normal
allele observed in our cohort. This individual presented
with rapidly progressive cognitive impairment and
balance problems at the age of 61 years old, hence there
was cognitive involvement at the onset of symptoms.
They underwent diagnostic tests for fragile X-associated
tremor/ataxia syndrome (FXTAS) and with a Dementia
Genetic Panel, but all tests were negative. MRI showed
cerebellar atrophy with additional frontoparietal cortical
atrophy. Their age at disease onset is consistent with
heterozygotes with 41 and 42 CAG/CAA repeats within
our cohort (subjects #14 and #18), in keeping with previous
studies (Zühlke C.H. et al., 2003; Toyoshima et al., 2004),
whilst the rapidly progressive dementia seen in our
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FIGURE 4 | Venn diagram showing the distribution of phenotypes within the cloned SCA17 cohort. Phenotype information was available for 25 patients out of the 30
individuals in the cohort. The number of patients falling into a specific symptom category is shown in black, whilst the subject numbers corresponding to the clone
frequency tables (Supplementary Tables S1, S2) are shown in dark blue. Patients with particular phenotypes are enclosed by the appropriate rounded rectangle
(Ataxia, blue; Dementia, green; Chorea, red; and Parkinsonism, brown). Five subjects either were asymptomatic or no phenotype information was available.
homozygote also fits with previously observed homozygotes
(Zühlke C.H. et al., 2003; Toyoshima et al., 2004).
Monozygotic Twins: Other Contributing
Factors to Age at Onset or Variable
Penetrance
Within the cloned cohort there were a pair of monozygotic twins,
subjects #13 and #16, whose pedigree is shown in Figure 5A.
They presented 3 years apart, both with memory impairment
followed by weight loss. Although there were no DNA samples
available from other family members to confirm SCA17, there
was a history of “fidgety hands” in one parent (who died aged 45
from breast cancer) and their grandparent. Interestingly, subject
#13 (II:1) not only presented 3 years earlier than their sibling,
but also had a more severe phenotype with dementia/cognitive
impairment and chorea in addition to the ataxia seen in
their sibling. Fragment sizing analysis shows that both twins
have the same pathogenic and normal allele sizes (48 and
38 repeats, respectively). Further analysis by clone sequencing
revealed that both twins have the same size pathogenic allele
(47 repeats) with a single repeat difference in their normal
alleles (38 and 37 repeats, respectively). However, this difference
could be explained by a single, potentially artefactual clone
of 34 repeats skewing the mean allele size in subject #16.
Indeed, the sequence of the twins’ repeat configurations were
also very similar. This could be a case of variable expressivity
or there may be other modulators influencing the age at
disease onset and severity such as environmental or epigenetic
factors.
Father and Child: Anticipation or Variable
Penetrance
Within the cloned cohort there were a father (subject #5, I:1)
and child (subject #4, II:3) who displayed a classic case of clinical
anticipation, whereby the father was asymptomatic at the age of
50 and the child first developed ataxic symptoms and slurred
speech at the age of 21 years old. Their pedigree is shown in
Figure 5B. Despite this anticipation in symptoms, there is no
concomitant expansion in the number of CAG repeats during
paternal transmission (the pathogenic allele contained 51 repeats
both by fragment sizing and clone sequencing). Examining the
clone sequences, both father and child have the same repeat
configurations in their pathogenic alleles. There is, however, a
difference in their normal alleles with the child having a slightly
larger allele size of 39 repeats compared to 37 repeats in their
father. STR analysis confirms that these are related, but not
identical samples (Supplementary Table S5). Since there is no
genetic basis for anticipation from intergenerational expansion
of the CAG/CAA repeat, this would suggest that this is a case of
variable penetrance, despite the pathogenic allele being within the
typical full penetrance range.
DISCUSSION
This study demonstrates the complexity in the genetic and
phenotypic presentation of SCA17, which poses a challenge for
geneticists and clinicians alike, who encounter SCA17 families in
genetic counseling. Here we present data from the largest United
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FIGURE 5 | Pedigrees of two case reports from the SCA17 cloned patient
cohort. The first family shows two monozygotic twins (II:1, subject #13; II:2,
subject #16), who have a clone sequenced mean pathogenic allele size of 47
repeats and mean normal alleles of 38 and 37 repeats, respectively (A).
Subject #13 (II:1) presented with a more severe phenotype compared to their
sibling, with an age of onset 3 years prior and dementia/cognitive impairment
and chorea in addition to the ataxia observed in their sibling (Subject #16, II:2).
The second family shows a father (I:1, subject #5) and child (II:3; subject #4)
where the father was asymptomatic at the age of 50 years old, whilst the child
developed ataxic symptoms at the age of 21 years old (B). Despite the
apparent anticipation, they both had a clone sequenced mean pathogenic
allele size of 51 repeats, but their normal alleles differed with the child having a
slightly larger mean allele size of 39 repeats compared to 37 repeats in their
father. DNA was only available for individuals who were cloned, with the given
subject number in italics.
Kingdom-based ataxic cohort to-date that was diagnostically
tested for SCA17 by the Neurogenetics Unit at The National
Hospital for Neurology and Neurosurgery, London. Out of the
658 genetic tests, the most frequent allele had 38 repeats (n = 354),
which is in keeping with previous studies (Alendar et al., 2004,
Nolte et al., 2010). The most frequent pathogenic allele was
in the variable penetrance range (41–48 repeats) and had 41
repeats (n = 14), whilst only five alleles were observed in the fully
penetrant range (≥49 repeats). The distribution observed in our
cohort is reflective of the data previously shown for a smaller
independent cohort from the north east of England (Craig et al.,
2005).
To understand whether the structure of the repeat can
modulate the phenotype in SCA17 we cloned and sequenced
the TBP gene CAG/CAA repeat tract from 30 individuals within
the cohort with variable or fully penetrant alleles of at least
41 repeats. 467 clones were sequenced with 61 unique repeat
region configurations. The most frequent allele sequence had 38
CAG/CAA repeats and comprised 10% of all clones generated,
which is in keeping with previous studies (Zühlke et al., 2001)
and fits with the greater population of the cohort analyzed by
diagnostic fragment analysis. It has been suggested that loss of
the (CAA)(CAG)(CAA) Domain III interruption between the
polymorphic CAG repeats of Domains II and IV may lead to
repeat instability (Zühlke et al., 2001; Maltecca et al., 2003). In
our cohort, the compete loss of this interruption is not observed
in any of the variable penetrant alleles (none of the 186 clones
between 41 and 48 repeats) and only seen in 6 out of 46 (13%)
of the fully penetrant allele clones. Indeed, there were only 2
clones with 40 repeats, and one clone each with 14, 25, 27, and
29 repeats lacking Domain III out of 235 normal allele clones.
This would suggest that if such instability events do occur they
are not incremental or stepwise, as one would expect to observe
clones lacking Domain III in the variable penetrance range,
however, examination of a larger cohort that includes families
with multiple generations would be required to confirm this. This
also suggests that such unstable alleles do not account for the
variability in penetrance of the SCA17 phenotype.
We examined the influence of the SCA17 allele repeat length
determined by both fragment sizing and clone sequencing on
the patients’ age at disease onset for 21 of the patients. We
found that there was a good negative correlation between age at
onset and total repeat length, in keeping with previous studies
(Toyoshima et al., 2004; Craig et al., 2005; Gao et al., 2008).
The data had a good fit to a linear model, which was further
improved when using mean pathogenic allele size determined
from clone sequencing compared to fragment sizing (R2 = 0.6005
vs. 0.595). For SCA1, we previously suggested that the longest
contiguous CAG repeat stretch was the main determinant of
age at disease onset (Menon et al., 2013). To validate whether
this was the case for SCA17, the mean longest CAG repeat
stretch determined by clone sequencing was plotted against
age at onset, however, we found no correlation between these
two variables. The complexity of the repeat configuration with
CAA interruptions that also encode glutamine at the protein
level would support total repeat length as being a main factor
in determining the age at onset. Since the CAA interruptions
are not completely lost in the expanded alleles in our cloned
cohort, the effect of the CAA interruption is unclear, however,
the secondary structures formed may have a stabilizing influence
during DNA replication and breaking up the repetitive sequence
into shorter homogenous triplet tracts could reduce slippage
between complementary strands (Choudhry et al., 2001; Zühlke
et al., 2005).
There is controversy over whether alleles with 41 and 42
repeats can be considered pathogenic given their frequency in
normal individuals (1.5 and 0.6%, respectively) (Shin et al., 2015).
In our cohort, we observe alleles with 41 and 42 repeats at a
similar frequency of 1.1 and 0.68%, respectively. However, we
have examined a cohort selected based on their genetic tests
for an ataxic phenotype or pre-symptomatic testing for such a
disorder. This introduces bias that means we cannot extrapolate
our findings to the general population. Although caution should
be used when referring to these alleles as pathogenic given the
potential for coincidental phenotypes occurring by chance, we
believe that they are indeed contributing to the phenotype in our
cohort since their inclusion in analysis improves the correlation
between pathogenic allele size and age at disease onset and the fit
to the linear model with tighter confidence interval boundaries
(Supplementary Figure S2).
Our cloned cohort had a diverse distribution of symptoms
when defined by the categories of ataxia, dementia, chorea, and
parkinsonism. Since most of these patients were referred for
SCA17 diagnostic testing based on their ataxic phenotype, it
was no surprise that 84% had ataxia as a symptom with 57% of
these also having another symptom be it dementia, chorea and/or
parkinsonism. Interestingly, two patients (8% of the cohort)
only had parkinsonism as a symptom. Previous studies have
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found that patients with 43–50 CAG/CAA repeats tend to have
symptoms resembling Huntington’s disease (dementia, chorea,
and parkinsonism) (Stevanin et al., 2003; Bauer et al., 2004;
Toyoshima et al., 2004), whilst those with 43–47 CAG/CAA
repeats tend to have a parkinsonian phenotype (Kim et al., 2009;
Chen et al., 2010). This does not appear to be the case in our
cohort with 3 out of 6 patients with chorea (subjects #3, #10,
#13; 50%), 1 out of 8 patients with dementia (subject #13; 12.5%),
and 3 out of 9 patients with parkinsonism (subjects #3, #7, #27;
33.3%) having 43–50 CAG/CAA repeats. There does not appear
to a particular repeat structure or length that can be associated
with a particular phenotype. This is probably due to several
other confounding factors including the variable expression and
penetrance of this condition.
Within our cloned cohort there was one patient who
was homozygous for SCA17 variable penetrance alleles of 41
and 42 CAG/CAA repeats. To date there have been four
homozygotes and one compound heterozygote reported (Zühlke
C.H. et al., 2003; Oda et al., 2004; Toyoshima et al., 2004;
Hire et al., 2011). Our patient had an age at onset that
was consistent with equivalent pathogenic allele heterozygotes
within our cohort, which is in keeping with previous reports
(Zühlke C.H. et al., 2003; Toyoshima et al., 2004). It is
interesting to note that this patient presented with severe
cognitive impairment with rapid progression despite the late
onset. This would suggest a contribution of the 41-repeat allele
to the pathogenesis of SCA17 in this patient even though
both alleles are at the lower end of the variable penetrance
range.
Within our cohort there was a pair of monozygotic twins.
Interestingly, they presented with symptoms 3 years apart and the
sibling that presented first (subject #13) also had a more severe
phenotype with dementia/cognitive impairment and chorea in
addition to ataxia that their sibling had. Clone sequencing
showed that they had the same mean pathogenic allele size
and similar repeat configurations. There was, however, a single
repeat difference in their normal alleles, which may be due
to a single potentially artefactual clone of 34 repeats skewing
the mean in subject #16. A striking phenotypic discordance
between monozygotic twins is not uncommon and has previously
been observed in twin studies for Huntington’s Disease and
SCA2 (Levy et al., 1999; Anderson et al., 2002; Panas et al.,
2008; Ketelaar et al., 2012). Although this could be viewed
as a case of variable expressivity, it is also possible that
there are other modulators influencing the age at disease
onset and disease severity such as environmental or epigenetic
factors.
A father and child within our cohort displayed marked
anticipation, whereby the father (subject #5) was asymptomatic
at the age of 50 and his child (subject #4) was severely affected at
the age of 21. However, they shared the same mean pathogenic
allele size with 51 repeats, which should be fully penetrant,
suggesting that there was no genetic basis for the anticipation.
They did, however, differ by two repeats in their normal allele
with the affected child having the larger normal allele. Such a
striking phenotypic difference with the same pathogenic allele
would suggest that this is a case of variable penetrance, possibly
influenced by other environmental or epigenetic factors. We
therefore recommend that the variable penetrance range be
extended from 48 repeats to incorporate this 51-repeat allele.
Interestingly, subject #9 within the cohort had a 52-repeat
pathogenic allele and an age at disease onset of 45 years old. This
patient showed cerebellar and cerebral atrophy at this age. By the
age of 59, subject #9 required a frame to walk and their cognitive
function was impaired. This demonstrates the variability in the
clinical presentation of SCA17 given a particular CAG/CAA
repeat tract size.
CONCLUSION
In conclusion, we have presented the distribution of allele sizes
across normal, variably penetrant and fully penetrant ranges in
the largest United Kingdom-based ataxic cohort to-date. We
found that fully penetrant alleles in our cohort were very rare (5
in 1,316 chromosomes; 0.38%). Cloning and sequencing a sub-
cohort of 30 individuals revealed no particular repeat structure
or length that could be associated with a particular SCA17
phenotype, however, there was a good negative correlation
between mean total pathogenic allele size and age at disease
onset. We observed a variable phenotype in a pair of monozygotic
twins, who had the same mean pathogenic allele size and repeat
structures, suggesting other factors such as environmental or
epigenetic factors are modulating their phenotype. Finally, we
found a stark dichotomy in the phenotype of an asymptomatic
father and severely affected child who share the same mean
pathogenic allele size of 51 repeats and consisting of the same
repeat structures. Since this mean pathogenic allele falls within
the existing fully penetrant range yet displays variable penetrance,
we advise that the variable penetrance range be increased from 48
repeats to include this allele.
This study has demonstrated the variability in the presentation
and penetrance of the SCA17 phenotype highlighting the
complexity of genetically diagnosing and counseling families with
this rare condition.
MATERIALS AND METHODS
Ethics Statement
This research has been approved by the London (Queen Square)
NHS Research Ethics Committee (reference 09/H0716/53) at the
National Hospital for Neurology and Neurosurgery, London.
Patient Cohort
Blood from patients with an ataxic phenotype or pre-
symptomatic family members were sent to the Neurogenetics
Unit at The National Hospital for Neurology and Neurosurgery,
London for SCA17 diagnostic testing. Thirty individuals were
selected for cloning and sequencing based on having SCA17
expanded alleles in the variable to fully penetrant range
(≥41 repeats). This cloned cohort consisted of 14 males
and 16 females with ages at disease onset ranging from 14
to 68 years old. Ethnicity was predominantly British (19
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individuals), whilst 5 were from the Indian subcontinent, 4 were
of Spanish/Mediterranean heritage, and 2 were of unknown
ethnicity. Fragment analysis and sequence information for an
additional four patients were available to us from the Institute of
Translational Pharmacology in Rome, Italy.
SCA17 Fragment Sizing
Genomic DNA was extracted from patient peripheral
blood leukocytes using a FlexiGene DNA kit (QIAGEN).
SCA17 alleles were amplified by PCR using GoTaq DNA
polymerase (Promega) and the primers SCA17For (FAM-
5′-GATGCCTTATGGCACTGGACTG-3′) and SCA17Rev
(5′-CTGCTGGGACGTTGACTGCTG-3′). PCR products were
checked on a 4% (w/v) agarose gel and then the fragments were
resolved on an ABI 3730xl DNA analyser with a GeneScan
500 LIZ Size Standard (Thermo Fisher Scientific). Fragment
analysis was performed with GeneMapper software (version
4.0, Applied Biosystems) and the most intense peak for each
allele was selected to calculate the allele size. Repeat lengths
were calculated by subtracting the number of extraneous bases
in the PCR product outside of the repeat region (120 bp) and
then dividing by 3. A correction factor of two repeats is then
added, based on the difference previously seen between fragment
analyzed and sequenced clones within the laboratory (data not
shown).
Cloning of SCA17 Allele
CAG/CAA-Repeat Tracts
Spinocerebellar ataxia type 17 allele CAG/CAA-repeat tracts
from 30 patients from this cohort were PCR amplified
using Phusion High-Fidelity DNA polymerase (New
England Biolabs) and primers which flank the CAG/CAA-
repeat region and introduce restriction enzyme cleavage
sites. The primers used were TBPx3 BamHI Forward (5′-
ATGTTTggatccTCCACAGGGTGCCATGAC-3′) and TBPx3
XhoI Reverse (5′-GGTTTGctcgagACACGAAGTACTCAC
TGC-3′), with restriction sites indicated in lower case. The PCR
reactions were processed and cloned into a pcDNA3.1(+) vector
similar to previously described for SCA1 alleles (Menon et al.,
2013) or pCR-Blunt using the Zero Blunt PCR Cloning Kit
(Thermo Fisher Scientific). Clone plasmids were propagated in
Stbl3 E. coli (Thermo Fisher Scientific) (genotype F− mcrB mrr
hsdS20(rB−, mB−) recA13 supE44 ara-14 galK2 lacY1 proA2
rpsL20(StrR) xyl-5 λ− leumtl-1). Plasmids were sequenced using
the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo
Fisher Scientific).
Sample Validation
The PowerPlex 16 HS System (Promega) was used to verify
sample identity for #13 and #16 (monozygotic twins) and #5 and
#4 (father and child, respectively). 0.5 and 1 ng genomic DNA
was used as template for the PCR amplification according to
the manufacturer’s protocol. Fragments were resolved on an ABI
3730xl DNA analyser (Thermo Fisher Scientific). Analysis was
performed using the Applied Biosystems Microsatellite Analysis
module on the Thermo Fisher Cloud.
Statistical Analysis
Analyses were only performed on individuals with a SCA17
diagnosis where age at disease onset data were available
(n = 21). A bivariate two-tailed Pearson correlation between the
pathogenic allele repeat size and the age at disease onset was
performed. In addition, the data were fit to a linear model of
the form “Age at Onset = A ∗ (Pathogenic Allele Size) + b.”
95% confidence interval bounds are shown. All statistics were
calculated in Prism (version 7.0d, GraphPad Software, Inc.).
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FIGURE S1 | The longest contiguous CAG repeat stretch in the SCA17
pathogenic allele size does not influence age at disease onset. Age at disease
onset data was available for 21 SCA17 patients that had been both analyzed by
fragment sizing and clone sequencing. Cloning and sequencing the SCA17 alleles
allows the configuration of the repeat tract to be determined. To examine whether
the longest contiguous CAG repeat stretch influenced the age at onset, similarly to
what we previously observed in SCA1 (Menon et al., 2013), the mean longest
CAG repeat stretch for each individual was plotted against age at onset. There
was no correlation between these two variables. The bold line depicts the linear
model fit result and the 95% confidence interval bounds are shown by the narrow
line and shaded in gray.
FIGURE S2 | Patients with 41 and 42 repeat alleles contribute to improving the
correlation between SCA17 pathogenic allele size and age at disease onset. Age
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at disease onset data was available for 21 SCA17 patients that had been both
analyzed by fragment sizing and clone sequencing and this data is plotted in red.
If patients with 41 and 42 repeats are excluded from the analysis, only 9 patients
remain, plotted in green. The bold line depicts the linear model fit result and the
95% confidence interval bounds are shown by the narrow line and shaded area. It
is clear that the inclusion of the patients with 41 and 42 repeats improves the
negative Pearson correlation (r) and the fit to the linear model (R2) with tighter
confidence interval boundaries.
TABLE S1 | Frequency with which each clone sequence was detected for each
individual in our cohort. The bold lines indicate the variable penetrance range
between 41 and 48 repeats. Domains 1–5 refer to the Domains I–V of the repeat
structure as depicted in Figure 1. 467 clones with 61 unique repeat region
sequences were analyzed from 30 individuals with variable of fully penetrant
SCA17 alleles.
TABLE S2 | Frequency with which each clone sequence was detected for each
individual in our cohort, corrected for the clone depth sequenced for each patient.
The bold lines indicate the variable penetrance range between 41 and 48 repeats.
Domains 1–5 refer to the Domains I–V of the repeat structure as depicted in
Figure 1. 467 clones with 61 unique repeat region sequences were analyzed from
30 individuals with variable of fully penetrant SCA17 alleles. The most frequent
allele had 38 CAG/CAA repeats and was found in 47/467 clones (10%). All repeat
configurations contained CAA interruptions.
TABLE S3 | Fragment and sequence analysis of SCA17 alleles in four patients in
an Italian cohort. SCA17 alleles were sized by fragment analysis and subsequently
sequenced at the Institute of Translational Pharmacology, Rome. Interestingly, two
of these patients, G31 and G32, lack the final (CAA/CAG) Domain V interruption
which is observed in all clones from the United Kingdom cohort bar one. These
patients also had a later age at disease onset for their expanded allele size,
compared to patients with similar sized alleles (#4, 51 repeats, 21 years; #9, 52
repeats, 45 years).
TABLE S4 | Summary of age at disease onset and allele size data for each
individual. Data is presented from both fragment sizing and clone sequencing
normal and expanded alleles. Age at onset data was available for 21 out of 30
individuals. Patient #8 (highlighted in blue italics) had a genetic diagnosis of
ARCA1/SCAR8 (see text), which explains the early age at onset despite the 41
repeat SCA17 allele. This data was used to compile the graphs
in Figure 3.
TABLE S5 | Short tandem repeat (STR) analysis to confirm identity of individuals
#4, 5, 13, and 16. The PowerPlex 16HS System was used to amplify
microsatellite markers at 15 STR loci. Numbers represent the alleles (repeat
numbers) at that locus. This data confirms that father (#5) and child (#4) are
separate samples and yet have the same 51-repeat pathogenic alleles with
marked difference in phenotype. The monozygotic twins (#13 and #16) share the
same alleles across all loci tested.
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